10x Genomics, Inc.
TXG · Healthcare
$59.98
Loading chart…
News
Latest headlines for this stock
TXG Stock Down Despite Patent Verdict Win Against Parse Biosciences
10x Genomics secured a favorable jury verdict against Parse Biosciences (a Qiagen subsidiary), winning $4.8M in damages for willful patent infringement on three single-cell analysis patents. The jury upheld all three patents' validity. 10x Genomics plans to seek enhanced damages, attorney fees, and a permanent U.S. injunction in post-trial proceedings. Despite the legal win, TXG shares fell over 5% following the announcement.
State of the Life Sciences Industry to Be Reviewed in BCC Research's 2026 Second Quarter Outlook, Spotlighting AI-Driven Discovery, Precision Oncology, and Connected Health Adoption
BCC Research's mid-year assessment highlights AI-driven discovery, precision oncology, and connected health as major growth themes in the life sciences sector. Key opportunities include smart inhalers with AI integration, genomic profiling platforms, cardiovascular drug innovations, and in vitro toxicity testing. The sector benefits from aging populations, regulatory support for non-animal testing, and emerging market expansion, though risks include patent expirations and reimbursement variability.
Precision Medicine Collaboration and Licensing Deals 2019-2026 | Gain Access to Over 1,350 Deals and Benchmark with Confidence
ResearchAndMarkets.com released a comprehensive report analyzing 1,350+ precision medicine collaboration and licensing deals from 2019-2026. The report provides detailed benchmarking data on deal structures, financial terms, and contract provisions to support business development and strategy decisions in the precision medicine sector.